Allotransplantation for patients with T1DM
OPEN ENROLLMENT
A Safety, Tolerability and Efficacy Study of Sernova Cell Pouch™ for Clinical Islet Transplantation.
Funded by Sernova/JDRF
Dear Patient,
I am writing to let you know about an opportunity to participate in a research study designed for patients with "brittle" form of Type 1 Diabetes.
This study is being conducted by myself, Dr. Piotr Witkowski at the University of Chicago. This research study will assess the safety, tolerability and efficacy of the Sernova Cell Pouch™ that will be implanted under the skin, and transplanted with islets.
You may be eligible for this study if:
-
you are between the ages of 18-65,
-
have been diagnosed with Type 1 Diabetes for longer than 5 years,
-
suffer from sudden and unpredictable drops of blood glucose leading to confusion or passing out despite the best medical treatment of insulin under the guidance of an experienced diabetologist.
If you are interested in learning more about the study, please contact our Research Manager Lindsay Basto, RN, MSN,
Lindsay.Basto@uchospitals.edu or call 773-702-2504 for additional information. You also will be given password to access Brief description of the study. You will be able to print Patient information package there as well.
At any time you can review our enrollment process: at Enroll Here, There are 2 forms to be filled out and emailed to us.
It is important to know that this letter is not to tell you to join the study.
It is your decision, and your participation is voluntary.
Whether you show interest, and participate in the study or not, it will have no effect on your treatment with your doctors. We would also like to let you know that Dr. Witkowski has a relationship with the study sponsor, Sernova Corp since he received financial compensation from the sponsor for designing the protocol of the study in 2016.
Thank you for your interest and consideration,
Piotr Witkowski M.D. Ph.D
More information on clinicaltrials.gov
Conference Presentation
The Transplantation Society Congress, Buenos Aires, 2022 Sept Abstract
Press Release